To explore the immune microenvironment changes throughout the serrated neoplasia pathway and their implications for immunotherapy in colorectal cancer, emphasizing their significance for treatment outcomes.
Key Findings:
Serrated neoplasia pathway accounts for 15%-30% of sporadic colorectal cancers, highlighting its clinical relevance.
Early immune surveillance features may be present in sessile serrated lesions before invasive transformation, indicating potential early intervention points.
Adaptive immunosuppressive programs may arise in parallel with immune checkpoint upregulation, suggesting a complex immune response.
Immune heterogeneity in serrated lesions may influence their progression and response to immunotherapy, necessitating tailored treatment approaches.
Interpretation:
The immune microenvironment is integral to understanding the biological heterogeneity of serrated lesions and their progression, which may inform future biomarker development and therapeutic strategies, particularly in immunotherapy.
Limitations:
Current evidence is not yet sufficient to alter clinical classification or treatment selection, particularly in terms of specific biomarkers.
Limited direct evidence in human serrated lesions regarding immune microenvironment changes, highlighting the need for further research.
Conclusion:
Understanding the immune microenvironment in serrated lesions is crucial for developing targeted therapies and improving risk stratification in colorectal cancer, with potential implications for clinical practice.
